Core Viewpoint - The SPD (Supply, Processing, Distribution) concept sector is experiencing significant market activity, with multiple stocks reaching their daily limit up, driven by the demand for upgraded pharmaceutical supply chain management services [1][2]. Group 1: Stock Performance - The SPD concept sector saw three stocks hit the daily limit up, including 华人健康 (China Health) at 20% increase, 英特集团 (Yingte Group) at 10.02%, and 塞力医疗 (Saili Medical) at 9.99% [1][2]. - Other notable performers include 漱玉平民 (Shuyupingmin) with an 11.78% increase, 思创医惠 (Sichuang Medical) at 9.13%, and 达嘉维康 (Dajia Weikang) at 8.40% [1][2]. Group 2: Market Dynamics - The core logic behind the market's interest in the SPD concept is the increasing demand for pharmaceutical supply chain management services, driven by policies aimed at controlling medical insurance costs and improving pharmaceutical distribution efficiency [1][3]. - The SPD model integrates procurement, warehousing, distribution, and settlement processes, helping medical institutions reduce operational costs and optimize inventory management, thus enhancing transparency and efficiency in the flow of pharmaceuticals and consumables [1][3]. Group 3: Impacted Sectors - The promotion of the SPD model is expected to reshape the pharmaceutical distribution industry, allowing companies with SPD service qualifications and resource advantages to expand their client base among medical institutions, transitioning from traditional distribution to full-process services, thereby increasing revenue scale and gross margins [3]. - The medical information technology sector will benefit from the SPD system's reliance on digital platforms, with companies providing medical supply chain information solutions likely to receive more orders, positioning technology leaders favorably in market competition [3]. - In the medical device consumables sector, the SPD model will lead to more centralized and efficient procurement and distribution, allowing production companies that collaborate closely with SPD service providers to reduce distribution costs and secure stable hospital channel orders, enhancing market share and profitability [3].

Core Viewpoint - 九州通's medical device segment showed strong growth in the first three quarters of 2025, with sales revenue reaching 28.963 billion yuan, a year-on-year increase of 17.20% [1] Group 1: Business Performance - The medical device business covers three main areas: OTC, medical, and professional services, demonstrating a diversified and collaborative development pattern [1] - In the OTC segment, 九州通 collaborated with well-known brands such as Yuyue, Sanor, Kefu Mei, and Durex, achieving comprehensive coverage across all categories and channels [1] - The online business saw significant growth due to the "old-for-new" policy for consumer goods, with related sales exceeding 537 million yuan in the first three quarters [1] Group 2: Medical Business - 九州通 focuses on high-value consumables in major surgical, vascular intervention, orthopedics, and IVD fields, establishing partnerships with over 60% of the global top 100 multinational companies and 80% of domestic top 100 industrial enterprises [1] - The sales revenue from medical equipment under the "old-for-new" policy reached 5 billion yuan, marking a 42% year-on-year increase [1] - The company accelerated the expansion of its SPD (Supply Processing Distribution) business, signing 28 new projects in the first three quarters, with a cumulative total of 132 bids won [1] Group 3: Professional Services - 九州通 continues to optimize its SPD system and digital service platforms such as the Orthopedic Chang'e platform, advancing the development of SPD smart cabinets [1] - The company achieved full tracking of personnel and goods in 3D trajectories, providing integrated supply chain solutions for hospitals [1]